Compound class:
Synthetic organic
Comment: PF-06939999 is an orally bioavailable, SAM-competitive PRMT5 inhibitor that was developed for ant-tumour potential [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
PF-06939999 has been advanced to clinical evaluation in splicing dysregulated non-small cell lung cancers. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Phase 1 Interventional | Pfizer |